Drug Profile
Research programme: autophagy inhibitors - Astellas Pharma/Cancer Research UK
Alternative Names: Cancer therapeutics - Astellas Pharma/Cancer Research UKLatest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator Cancer Research UK
- Developer Astellas Pharma; Cancer Research UK
- Class
- Mechanism of Action Autophagy inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for research development in Pancreatic-cancer in United Kingdom
- 08 Aug 2014 Early research in Pancreatic cancer in United Kingdom (unspecified route)